{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:16:40Z","timestamp":1762460200507,"version":"3.40.5"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Patients with <jats:italic>FLT3<\/jats:italic>\u2010mutated acute myeloid leukaemia (AML) that relapse or are refractory (R\/R) to intensive induction have poor outcomes. Gilteritinib has recently become standard\u2010of\u2010care for patients with R\/R <jats:italic>FLT3<\/jats:italic>\u2010mutated AML. We investigated whether adding venetoclax to gilteritinib (gilt\u2010ven) improves outcomes as compared with gilteritinib monotherapy. We included patients treated with gilteritinib (<jats:italic>n<\/jats:italic>\u2009=\u200919) and gilt\u2010ven (<jats:italic>n<\/jats:italic>\u2009=\u200917) for R\/R AML after intensive chemotherapy. Gilteritinib and gilt\u2010ven groups did not differ in terms of mCRc rates (53% and 65%, <jats:italic>p<\/jats:italic>\u2009=\u20090.51) and realization of allogeneic haematopoietic stem\u2010cell transplantation (HSCT, 47% and 35%, <jats:italic>p<\/jats:italic>\u2009=\u20090.5). Overall survival (OS) was comparable between groups, although a trend towards better OS was seen with gilt\u2010ven (12\u2010month OS 58.8% [95% CI 39.5%\u201387.6%]) versus gilteritinib (42.1% [95% CI 24.9%\u201371.3%] for gilteritinib). Early salvage with gilt\u2010ven versus any other gilteritinib\u2010based approach was associated with the best outcome (<jats:italic>p<\/jats:italic>\u2009=\u20090.031). Combination therapy was associated with increased haematological toxicity. In summary, gilt\u2010ven did not improve remissions or HSCT\u2010realization rates in patients with R\/R <jats:italic>FLT3<\/jats:italic>\u2010mutated AML as compared with gilteritinib and was associated with increased haematological toxicity. Although OS did not differ, a trend towards better survival was suggested with gilt\u2010ven and a survival benefit was shown for gilt\u2010ven approach when sequenced early for salvage.<\/jats:p>","DOI":"10.1111\/bjh.19548","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T01:18:39Z","timestamp":1716513519000},"page":"932-941","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Gilteritinib with or without venetoclax for relapsed\/refractory <i>FLT3<\/i>\u2010mutated acute myeloid leukaemia"],"prefix":"10.1111","volume":"205","author":[{"given":"Eitan","family":"Kugler","sequence":"first","affiliation":[{"name":"Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center\u2014Beilinson Hospital  Petach Tikva Israel"},{"name":"Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"},{"name":"The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inbar","family":"Cohen","sequence":"additional","affiliation":[{"name":"Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center\u2014Beilinson Hospital  Petach Tikva Israel"},{"name":"Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Amitai","sequence":"additional","affiliation":[{"name":"Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"},{"name":"Haematology Division Chaim Sheba Medical Center  Tel Hashomer Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Ram","sequence":"additional","affiliation":[{"name":"Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"},{"name":"Institute of Haematology, Tel\u2010Aviv Sourasky Medical Center (TLVMC)  Tel\u2010Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avraham","family":"Frisch","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Rambam Health Care Campus  Haifa Israel"},{"name":"Bruce Rappaport Faculty of Medicine Technion, Israel Institute of Technology  Haifa Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boaz","family":"Nachmias","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hadassah Medical Center and Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Canaani","sequence":"additional","affiliation":[{"name":"Weill Medical College of Cornell University  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yakir","family":"Moshe","sequence":"additional","affiliation":[{"name":"Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"},{"name":"Institute of Haematology, Tel\u2010Aviv Sourasky Medical Center (TLVMC)  Tel\u2010Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baher","family":"Krayem","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Rambam Health Care Campus  Haifa Israel"},{"name":"Bruce Rappaport Faculty of Medicine Technion, Israel Institute of Technology  Haifa Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shlomzion","family":"Aumann","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hadassah Medical Center and Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Henig","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation Rambam Health Care Campus  Haifa Israel"},{"name":"Bruce Rappaport Faculty of Medicine Technion, Israel Institute of Technology  Haifa Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-4094","authenticated-orcid":false,"given":"Vladimir","family":"Vainstein","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hadassah Medical Center and Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6429-148X","authenticated-orcid":false,"given":"Liat","family":"Shargian","sequence":"additional","affiliation":[{"name":"Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center\u2014Beilinson Hospital  Petach Tikva Israel"},{"name":"Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-4807","authenticated-orcid":false,"given":"Chezi","family":"Ganzel","sequence":"additional","affiliation":[{"name":"Department of Haematology, Shaare Zedek Medical Center, Faculty of Medicine Hebrew University  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Yeshurun","sequence":"additional","affiliation":[{"name":"Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center\u2014Beilinson Hospital  Petach Tikva Israel"},{"name":"Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itay","family":"Levi","sequence":"additional","affiliation":[{"name":"Haematology Institute, Soroka Medical Center  Beer\u2010Sheba Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[{"name":"Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center\u2014Beilinson Hospital  Petach Tikva Israel"},{"name":"Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiza","family":"Akria","sequence":"additional","affiliation":[{"name":"Department of Haematology, Galilee Medical Center, Naharyia Azrieli Faculty of Medicine Bar Ilan University  Sefad Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5521-1337","authenticated-orcid":false,"given":"Yishai","family":"Ofran","sequence":"additional","affiliation":[{"name":"Department of Haematology, Shaare Zedek Medical Center, Faculty of Medicine Hebrew University  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9652","authenticated-orcid":false,"given":"Shai","family":"Shimony","sequence":"additional","affiliation":[{"name":"Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center\u2014Beilinson Hospital  Petach Tikva Israel"},{"name":"Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"},{"name":"Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8662-0707","authenticated-orcid":false,"given":"Ofir","family":"Wolach","sequence":"additional","affiliation":[{"name":"Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center\u2014Beilinson Hospital  Petach Tikva Israel"},{"name":"Faculty of Medical and Health Sciences Tel Aviv University  Tel Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.25"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-693648"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.10.001"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00464-6"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011583"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00973-4"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014241"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0832"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2339"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00578-4"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00602"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04895-8"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_2_14_17_1","unstructured":"National Cancer Institute.N.I.o.H. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_5.0\/. Published Jan 3 2018"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040773"},{"key":"e_1_2_14_19_1","unstructured":"CortesJ KhaledS MartinelliG PerlAE GangulyS RussellN et\u00a0al.Quizartinib significantly prolongs overall survival in patients with FLT3\u2010internal tandem duplication\u2010mutated (MUT) relapsed\/refractory AML in the phase 3 randomized controlled Quantum\u2010R trial.2019EHA23 (abstr LB2600)."},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.12.006"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000534897"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01911"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19182"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2392823"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00677-7"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26447"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01742-7"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T13:51:29Z","timestamp":1729691489000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/bjh.19548"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19548","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"2024-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}